Cargando…

Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression—real-world clinical practice

BACKGROUND: Semaglutide [glucagon-like peptide-1 receptor-agonist (GLP-1RA)] has shown nephroprotective effects in previous cardiovascular studies. However, its efficacy and safety in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) have been rarely studied. METHODS: This is a mu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aviles Bueno, Beatriz, Soler, Maria Jose, Perez-Belmonte, Luis, Jimenez Millan, Anabel, Rivas Ruiz, Francisco, Garcia de Lucas, Maria Dolores
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308087/ https://www.ncbi.nlm.nih.gov/pubmed/35892023 http://dx.doi.org/10.1093/ckj/sfac096

Ejemplares similares

Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain
por: Garcia de Lucas, Maria Dolores, et al.
Publicado: (2022)

Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type 2 diabetes patients: a multicenter real-world study
por: García de Lucas, María Dolores, et al.
Publicado: (2023)

Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice
por: Pérez-Belmonte, Luis M., et al.
Publicado: (2022)

Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany
por: Menzen, Markus, et al.
Publicado: (2023)

Acute Kidney Injury Associated With Semaglutide
por: Leehey, David J., et al.
Publicado: (2021)

Effect of Semaglutide on Subclinical Atherosclerosis and Cardiometabolic Compensation: A Real-World Study in Patients with Type 2 Diabetes
por: Patti, Angelo Maria, et al.
Publicado: (2023)

Real-World Clinical Experience of Semaglutide in Secondary Care Diabetes: A Retrospective Observational Study
por: Williams, David M., et al.
Publicado: (2021)

Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients
por: Marzullo, P., et al.
Publicado: (2022)

Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: A retrospective, cohort study (Sema-MiDiab01)
por: Berra, Cesare C., et al.
Publicado: (2023)

Real-World Retrospective Study into the Effects of Oral Semaglutide (As a Switchover or Add-On Therapy) in Type 2 Diabetes
por: Candido, Riccardo, et al.
Publicado: (2023)

Use of Linagliptin for the Management of Medicine Department Inpatients with Type 2 Diabetes in Real-World Clinical Practice (Lina-Real-World Study)
por: Pérez-Belmonte, Luis M., et al.
Publicado: (2018)

Oral Semaglutide
por: Bui, Vinh, et al.
Publicado: (2018)

Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)

Once-Weekly Semaglutide Use in Type 2 Diabetes: Real-World Data from the SURE Netherlands Observational Study
por: Wolffenbuttel, Bruce H. R., et al.
Publicado: (2022)

Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis
por: Mann, Johannes F. E., et al.
Publicado: (2021)

Semaglutide once weekly in people with type 2 diabetes: Real‐world analysis of the Canadian LMC diabetes registry (SPARE study)
por: Brown, Ruth E, et al.
Publicado: (2020)

Real-World Use of Once-Weekly Semaglutide in Thai Patients With Type 2 Diabetes Mellitus in a Private Hospital Setting
por: Thewjitcharoen, Yotsapon, et al.
Publicado: (2023)

Corrigendum: Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)

Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from the SURE UK Multicentre, Prospective, Observational Study
por: Holmes, Patrick, et al.
Publicado: (2021)

The Discovery and Development of Liraglutide and Semaglutide
por: Knudsen, Lotte Bjerre, et al.
Publicado: (2019)

Semaglutide for type 2 diabetes
Publicado: (2020)

Semaglutide-associated bullous pemphigoid
por: Burruss, Clayton P., et al.
Publicado: (2021)

Semaglutide-eye-catching results
por: Cigrovski Berkovic, Maja, et al.
Publicado: (2023)

Emerging Anesthesia Risks with Semaglutide
por: Fezza, Reed, et al.
Publicado: (2023)

Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With Type 2 Diabetes Mellitus: The Retrospective REALISE-DM Study
por: Jain, Akshay B., et al.
Publicado: (2020)

Outcomes in GLP-1 RA-Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study
por: Lingvay, Ildiko, et al.
Publicado: (2021)

Case study of semaglutide and cardiovascular outcomes: An application of the Causal Roadmap to a hybrid design for augmenting an RCT control arm with real-world data
por: Dang, Lauren E., et al.
Publicado: (2023)

Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise: 6‐month follow‐up from US real‐world data
por: Mody, Reema, et al.
Publicado: (2020)

Semaglutide for treatment of obesity in hemodialysis patients waiting for a kidney transplant: new hope?
por: Touzot, Maxime, et al.
Publicado: (2022)

Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a US Real-World Setting
por: Uzoigwe, Chioma, et al.
Publicado: (2021)

Efficacy and Safety of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist in Real-Life: A Case Series of Patients in Maintenance Incremental Hemodialysis
por: De la Flor, José C., et al.
Publicado: (2022)

Oral Semaglutide: Dosage in Special Situations
por: Kalra, Sanjay, et al.
Publicado: (2022)

Semaglutide in Obesity: Unmet Needs in Men
por: Jensterle, Mojca, et al.
Publicado: (2023)

Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups
por: Yale, Jean-François, et al.
Publicado: (2022)

Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon‐like peptide‐1 receptor agonists
por: Crabtree, Thomas S. J., et al.
Publicado: (2022)

A real-world study on SGLT2 inhibitors and diabetic kidney disease progression
por: Liu, Allen Yan Lun, et al.
Publicado: (2022)

THU283 Oral Semaglutide, Effectiveness, Safety And Tolerability In Real Life: A Short-term Retrospective Observational Study
por: Moreno-Perez, Oscar, et al.
Publicado: (2023)

Evaluation of dried blood spot samples for screening of hepatitis C and human immunodeficiency virus in a real-world setting
por: Vázquez-Morón, Sonia, et al.
Publicado: (2018)

Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment
por: Jensen, Lene, et al.
Publicado: (2018)

Population Pharmacokinetics of Semaglutide for Type 2 Diabetes
por: Overgaard, Rune V., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4ri9ogbj60s1eqr8eke6ij2uht